Comparative Risk of Ischemic Stroke Among Users of Clopidogrel Together With Individual Proton Pump Inhibitors
- 1 March 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 46 (3) , 722-731
Abstract
Background and Purpose— There is controversy and little information about whether individual proton pump inhibitors (PPIs) differentially alter the effectiveness of clopidogrel in reducing ischemic stroke risk. We, therefore, aimed to elucidate the risk of ischemic stroke among concomitant users of clopidogrel and individual PPIs. Methods— We conducted a propensity score-adjusted cohort study of adult new users of clopidogrel, using 1999 to 2009 Medicaid claims from 5 large states. Exposures were defined by prescriptions for esomeprazole, lansoprazole, omeprazole, rabeprazole, and pantoprazole—with pantoprazole serving as the referent. The end point was hospitalization for acute ischemic stroke, defined by International Classification of Diseases Ninth Revision Clinical Modification codes in the principal position on inpatient claims, within 180 days of concomitant therapy initiation. Results— Among 325 559 concomitant users of clopidogrel and a PPI, we identified 1667 ischemic strokes for an annual incidence of 2.4% (95% confidence interval, 2.3–2.5). Adjusted hazard ratios for ischemic stroke versus pantoprazole were 0.98 (0.82–1.17) for esomeprazole; 1.06 (0.92–1.21) for lansoprazole; 0.98 (0.85–1.15) for omeprazole; and 0.85 (0.63–1.13) for rabeprazole. Conclusions— PPIs of interest did not increase the rate of ischemic stroke among clopidogrel users when compared with pantoprazole, a PPI thought to be devoid of the potential to interact with clopidogrel.Keywords
This publication has 46 references indexed in Scilit:
- Amphetamines, Atomoxetine and the Risk of Serious Cardiovascular Events in AdultsPLOS ONE, 2013
- Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel BioactivationACS Medicinal Chemistry Letters, 2012
- The Proton Pump Inhibitor, Omeprazole, but Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with ClopidogrelDrug Metabolism and Disposition, 2011
- Confounding adjustment via a semi‐automated high‐dimensional propensity score algorithm: an application to electronic medical recordsPharmacoepidemiology and Drug Safety, 2011
- Antidepressant-Warfarin Interaction and Associated Gastrointestinal Bleeding Risk in a Case-Control StudyPLOS ONE, 2011
- Drug-Drug Interaction Profiles of Proton Pump InhibitorsClinical Pharmacokinetics, 2010
- Fibrate/Statin Initiation in Warfarin Users and Gastrointestinal Bleeding RiskThe American Journal of Medicine, 2010
- Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active MetaboliteDrug Metabolism and Disposition, 2010
- Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and ClopidogrelThe Journal of Clinical Pharmacology, 2008
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983